Psychiatric illnesses commonly demand long-term administration of antipsychotic medications, where maintaining consistent therapeutic exposure and improving treatment adherence remain major clinical challenges. Traditional oral and injectable formulations may result in variable bioavailability, metabolic degradation, and irregular plasma drug levels, potentially compromising therapeutic outcomes. Delivery of antipsychotic agents across the skin offers an alternative approach aimed at achieving steady systemic absorption over an extended period. By allowing gradual diffusion of drug molecules into circulation, transdermal systems may reduce peak–trough fluctuations and decrease dosing frequency. These systems are typically engineered using drug-incorporated polymeric frameworks combined with skin permeation facilitators and adhesive interfaces designed to ensure controlled release and adequate contact with the application site. Different structural configurations influence drug release behavior and overall performance. Emerging technologies, including microstructured delivery platforms and responsive patch designs, are expanding the feasibility of this route for central nervous system therapies. Although limitations such as restricted skin permeability and physicochemical constraints of certain drugs remain, transdermal administration represents a promising strategy for enhancing therapeutic consistency and patient convenience in antipsychotic treatment.
Himanshu Gupta*1, Divyesh Gawand1, Siddhi Ghatkar1, Gayatri Jadhav1, Prafull Jadhav1 (Wed,) studied this question.